Zhang Ming
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhang Ming has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aelaf Mammo
Wachemo University, College of Medicine, Nigist Eleni Mohammed Memorial Comprehensive Specialized Hospital, Hossana, Ethiopia
1 shared publication - Amirhossein Farahani
Xi’an Jiaotong University School of Medicine, Xi’an, China
1 shared publication - Gulnaz Bahtiyarova
Department of Internal Medicine, Formerly: First Pavlov State Medical University, Saint Petersburg, Russia
1 shared publication - Hemeesh Tandel
C U Shah Medical College Surendranagar Gujarat India
1 shared publication - Karrar Imran
Faculty of Medicine, University of Warith Al-Anbiya, Karbala, Iraq
1 shared publication - Mirab Singh
Department of Emergency, Mediciti Hospital, Kathmandu, Nepal
1 shared publication
Latest Publications
- 17 January 2025
- Published by Science Publishing Group in American Journal of Internal Medicine
- Vol. 13 (1) , 1-6
Emotional Turmoil: A Case of Takotsubo Cardiomyopathy in a Young Adult
Takotsubo cardiomyopathy (TTC), or "broken heart syndrome," is a transient cardiac condition marked by left ventricular dysfunction, often triggered by emotional or physical stress. This case report discusses a 28-year-old female who developed TTC after the sudden loss of a close family member. She presented to the emergency department with acute chest pain, dyspnea, and anxiety, resembling acute myocardial infarction. ECG showed ST-segment elevations and T-wave inversions, while lab tests revealed elevated cardiac biomarkers, including troponin. An echocardiogram confirmed classic apical ballooning, and coronary angiography ruled out obstructive coronary artery disease, showing normal arteries. The patient received supportive care, including beta-blockers and anxiolytics, and her symptoms improved, with follow-up echocardiography showing normal left ventricular function within weeks. This case highlights the need for awareness of TTC in younger patients under emotional stress and the importance of timely diagnosis and management to avoid unnecessary interventions.
- 17 January 2025
- Published by Science Publishing Group in American Journal of Internal Medicine
- Vol. 13 (1) , 1-6
Emotional Turmoil: A Case of Takotsubo Cardiomyopathy in a Young Adult
Takotsubo cardiomyopathy (TTC), or "broken heart syndrome," is a transient cardiac condition marked by left ventricular dysfunction, often triggered by emotional or physical stress. This case report discusses a 28-year-old female who developed TTC after the sudden loss of a close family member. She presented to the emergency department with acute chest pain, dyspnea, and anxiety, resembling acute myocardial infarction. ECG showed ST-segment elevations and T-wave inversions, while lab tests revealed elevated cardiac biomarkers, including troponin. An echocardiogram confirmed classic apical ballooning, and coronary angiography ruled out obstructive coronary artery disease, showing normal arteries. The patient received supportive care, including beta-blockers and anxiolytics, and her symptoms improved, with follow-up echocardiography showing normal left ventricular function within weeks. This case highlights the need for awareness of TTC in younger patients under emotional stress and the importance of timely diagnosis and management to avoid unnecessary interventions.
- Open Access
- 13 November 2024
- Published by Science Publishing Group in American Journal of Internal Medicine
- Vol. 12 (6) , 120-124
Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Decompensated Post-Hepatitis B Cirrhosis: A Case Report
End-stage liver disease (ESLD) represents the terminal phase of chronic liver injury, characterized by overt clinical manifestations and severe complications that significantly impair the quality of life. The condition often culminates in a variety of symptoms, including jaundice, ascites, and hepatic encephalopathy, which reflect the liver's inability to perform its essential functions. Liver transplantation remains the definitive treatment for ESLD; however, limitations in donor organ availability necessitate exploration of alternative therapeutic strategies. we present a case of a 71-year-old Asian male with decompensated post-hepatitis B cirrhosis, who had a one-year history of hematemesis and melena. Endoscopic evaluation confirmed the presence of esophageal-gastric varices, further corroborating portal hypertension and hypersplenism. This patient underwent treatment with autologous bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation. Following the procedure, the patient demonstrated significant clinical improvement, suggesting the safety and potential feasibility of BM-MSC transplantation for patients with ESLD. The field of BM-MSC transplantation has witnessed significant progress in recent years, emerging as a promising therapeutic approach for ESLD. This innovative treatment modality harnesses the regenerative capabilities of stem cells to promote liver repair and function. Notably, BM-MSCs possess immunomodulatory properties that may mitigate inflammation and fibrosis in the liver, thereby addressing some of the underlying pathophysiology associated with ESLD. This case presentation highlights the potential application of BM-MSC therapy in patients with decompensated cirrhosis. The findings underscore the need for further research and refinement of clinical application techniques to fully realize the broad therapeutic possibilities of BM-MSC transplantation for ESLD. As we advance our understanding of stem cell therapies, it is crucial to conduct larger studies to evaluate long-term outcomes and establish standardized protocols for treatment.
- 13 November 2024
- Published by Science Publishing Group in American Journal of Internal Medicine
- Vol. 12 (6) , 120-124
Open AccessAutologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Decompensated Post-Hepatitis B Cirrhosis: A Case Report
End-stage liver disease (ESLD) represents the terminal phase of chronic liver injury, characterized by overt clinical manifestations and severe complications that significantly impair the quality of life. The condition often culminates in a variety of symptoms, including jaundice, ascites, and hepatic encephalopathy, which reflect the liver's inability to perform its essential functions. Liver transplantation remains the definitive treatment for ESLD; however, limitations in donor organ availability necessitate exploration of alternative therapeutic strategies. we present a case of a 71-year-old Asian male with decompensated post-hepatitis B cirrhosis, who had a one-year history of hematemesis and melena. Endoscopic evaluation confirmed the presence of esophageal-gastric varices, further corroborating portal hypertension and hypersplenism. This patient underwent treatment with autologous bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation. Following the procedure, the patient demonstrated significant clinical improvement, suggesting the safety and potential feasibility of BM-MSC transplantation for patients with ESLD. The field of BM-MSC transplantation has witnessed significant progress in recent years, emerging as a promising therapeutic approach for ESLD. This innovative treatment modality harnesses the regenerative capabilities of stem cells to promote liver repair and function. Notably, BM-MSCs possess immunomodulatory properties that may mitigate inflammation and fibrosis in the liver, thereby addressing some of the underlying pathophysiology associated with ESLD. This case presentation highlights the potential application of BM-MSC therapy in patients with decompensated cirrhosis. The findings underscore the need for further research and refinement of clinical application techniques to fully realize the broad therapeutic possibilities of BM-MSC transplantation for ESLD. As we advance our understanding of stem cell therapies, it is crucial to conduct larger studies to evaluate long-term outcomes and establish standardized protocols for treatment.